 |
 |
 |
Sažetak sa skupa
Pentadecapeptide BPC 157 therapy in bile duct ligated (bdl) rats
Ivan Krezić
Marko Antunović
Dominik Malekinušić
Emma Orešković
Pavla Peraić
Josh Fry
Marko Belamarić
| Puni tekst: engleski, pdf (68 KB) | str. 0-0 | citiraj | |
|
APA 6th Edition Krezić, I., Antunović, M., Malekinušić, D., Orešković, E., Peraić, P., Fry, J. i Belamarić, M. (2019). Pentadecapeptide BPC 157 therapy in bile duct ligated (bdl) rats. Liječnički vjesnik, 141 (suppl.1), 0-0. Preuzeto s https://hrcak.srce.hr/221770 MLA 8th Edition Krezić, Ivan, et al. "Pentadecapeptide BPC 157 therapy in bile duct ligated (bdl) rats." Liječnički vjesnik, vol. 141, br. suppl.1, 2019, str. 0-0. https://hrcak.srce.hr/221770. Citirano 14.12.2019. Chicago 17th Edition Krezić, Ivan, Marko Antunović, Dominik Malekinušić, Emma Orešković, Pavla Peraić, Josh Fry i Marko Belamarić. "Pentadecapeptide BPC 157 therapy in bile duct ligated (bdl) rats." Liječnički vjesnik 141, br. suppl.1 (2019): 0-0. https://hrcak.srce.hr/221770 Harvard Krezić, I., et al. (2019). 'Pentadecapeptide BPC 157 therapy in bile duct ligated (bdl) rats', Liječnički vjesnik, 141(suppl.1), str. 0-0. Preuzeto s: https://hrcak.srce.hr/221770 (Datum pristupa: 14.12.2019.) Vancouver Krezić I, Antunović M, Malekinušić D, Orešković E, Peraić P, Fry J i sur. Pentadecapeptide BPC 157 therapy in bile duct ligated (bdl) rats. Liječnički vjesnik [Internet]. 2019 [pristupljeno 14.12.2019.];141(suppl.1):0-0. Dostupno na: https://hrcak.srce.hr/221770 IEEE I. Krezić, et al., "Pentadecapeptide BPC 157 therapy in bile duct ligated (bdl) rats", Liječnički vjesnik, vol.141, br. suppl.1, str. 0-0, 2019. [Online]. Dostupno na: https://hrcak.srce.hr/221770. [Citirano: 14.12.2019.] |
|||
Sažetak
Pentadecapeptide BPC 157 demonstrates beneficial healing and anti-inflammatory effects on gastrointestinal and many extra - gastrointestinal tissues. Bile duct ligation causes inflammation and fibrotic changes in the liver. We wanted to explore effect of BPC 157 on bile duct ligation (BDL) in rats. Rats received BPC 157 perorally, in drinking water (0.16μg/ml, 0.16ng/ml,), or 10 μg/kg, 10 ng/kg intraperitoneally, first application at 30 min after surgery, last at 24h before sacrifice. Alternatively, delayed therapy, BPC 157 perorally, in drinking water (0.16μg/ml), started at the end of week 4 . Controls received simultaneously drinking water or an equal volume of saline (5ml/kg) intraperitoneally. At the end of the 2nd week, quantitative measurement of IL-1, IL-6 and TNF-α has been utilized using ELISA kits and NOS-3 Western Blot Analysis was performed. For assessing cell proliferation rate antibodies of monoclonal mouse Ki-67 were used at the 2, 4, 6, 8 week of BDL. Western blot analysis of NOS-3 expression in liver tissue showed that BPC 157 decreased the expression of NOS-3 protein. At 2 weeks, BDL-rat regularly exhibited the increased TNF-α, IL-6 and IL-1β liver levels but these values were counteracted with the administration of BPC 157 in drinking water. Since 2nd week until the 8th week, we noted decreased LI of Ki-67. This research shows that BPC 157 decreases hepatocyte proliferative activity, counteracts increased NOS–3 expresion, as well as increased IL-6, TNF-α, IL-1β in liver tissue.
Ključne riječi
BPC 157, bile duct ligation, liver fibrosis
Hrčak ID: 221770
URI
https://hrcak.srce.hr/221770
Moj profil